Now Reading: Molbio Diagnostics IPO to raise Rs 940 crore, reduce promoter stake
-
01
Molbio Diagnostics IPO to raise Rs 940 crore, reduce promoter stake
Molbio Diagnostics IPO to raise Rs 940 crore, reduce promoter stake
Molbio Diagnostics plans to raise Rs 200 crore through a fresh issue and Rs 740 crore through an offer for sale, the Economic Times reports. The promoter group's stake will fall to…
The Story in Brief
Molbio Diagnostics plans to raise Rs 200 crore through a fresh issue and Rs 740 crore through an offer for sale, the Economic Times reports. The promoter group's stake will fall to 43% from 46.6% after the IPO. The company, known for its portable Truenat diagnostic platform, gets nearly three-fourths of its revenue from test kits, with tuberculosis kits alone contributing 70% of that. Revenue grew 31.5% annually to Rs 1,445.7 crore and net profit rose 40.2% annually to Rs 164.1 crore between FY24 and FY26. However, over four-fifths of revenue comes from government and international aid agencies, and the top clients contribute more than half of sales, indicating high customer concentration.
The Indian Opinion
The hype around Truenat and TB test kits paints Molbio as a sure long-term winner, but the story is more nuanced. Over 80% of revenue comes from government and aid agencies, and the top clients account for more than half of sales, a dangerous concentration for a company asking for a P/E of 57. The promoter stake drop from 46.6% to 43% is modest. A fair test will be whether the company can diversify its customer base beyond its largest buyers in the next three years.
Source: economictimes.indiatimes.com
This story was synthesised by AI from the source linked above.
